Wells Fargo
CABA icon

Wells Fargo’s Cabaletta Bio CABA Stock Holding History

Wells Fargo’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612K Buy
196,872
+190,872
+3,181% +$628K ﹤0.01% 4475
2026
Q1 		$16.1K Buy
6,000
+4,000
+200% +$11.1K ﹤0.01% 5845
2025
Q4 		$4.38K Sell
2,000
-1,000
-33% -$2.48K ﹤0.01% 6129
2025
Q3 		$7.02K Sell
3,000
-3,686
-55% -$6.32K ﹤0.01% 6015
2025
Q2 		$10.2K Sell
6,686
-25,293
-79% -$39.4K ﹤0.01% 5949
2025
Q1 		$44.3K Sell
31,979
-8,433
-21% -$18K ﹤0.01% 5441
2024
Q4 		$91.7K Buy
40,412
+16,250
+67% +$57.1K ﹤0.01% 5244
2024
Q3 		$114K Buy
24,162
+4,853
+25% +$28.1K ﹤0.01% 4935
2024
Q2 		$144K Buy
19,309
+5,934
+44% +$72.7K ﹤0.01% 4722
2024
Q1 		$228K Sell
13,375
-683
-5% -$14.7K ﹤0.01% 4392
2023
Q4 		$319K Sell
14,058
-16,985
-55% -$286K ﹤0.01% 4172
2023
Q3 		$472K Buy
31,043
+17,307
+126% +$237K ﹤0.01% 3822
2023
Q2 		$177K Buy
13,736
+11,683
+569% +$127K ﹤0.01% 4654
2023
Q1 		$17K Buy
2,053
+735
+56% +$6.88K ﹤0.01% 5698
2022
Q4 		$12.2K Sell
1,318
-2,496
-65% -$9.09K ﹤0.01% 5471
2022
Q3 		$2K Buy
3,814
+32
+0.8% +$39 ﹤0.01% 6134
2022
Q2 		$4K Buy
3,782
+119
+3% +$168 ﹤0.01% 6069
2022
Q1 		$7K Sell
3,663
-11,767
-76% -$30.8K ﹤0.01% 6378
2021
Q4 		$58K Sell
15,430
-7,554
-33% -$80.6K ﹤0.01% 5892
2021
Q3 		$280K Buy
22,984
+124
+0.5% +$1.14K ﹤0.01% 4960
2021
Q2 		$197K Sell
22,860
-2,431
-10% -$23.9K ﹤0.01% 5035
2021
Q1 		$280K Sell
25,291
-25,793
-50% -$315K ﹤0.01% 5003
2020
Q4 		$637K Buy
51,084
+15,874
+45% +$206K ﹤0.01% 4351
2020
Q3 		$382K Sell
35,210
-49,258
-58% -$566K ﹤0.01% 4543
2020
Q2 		$941K Buy
84,468
+76,361
+942% +$585K ﹤0.01% 3858
2020
Q1 		$59K Buy
8,107
+7,576
+1,427% +$104K ﹤0.01% 5282
2019
Q4 		$7K Buy
+531
New +$6.29K ﹤0.01% 5968

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Wells Fargo's CABA Position: Q2 2026 in Review

Wells Fargo increased its Cabaletta Bio (CABA) stake by 3,181% in Q2 2026, buying an estimated $628K and bringing the position to 196,872 shares worth $612K. The position accounts for ﹤0.01% of the portfolio, ranked #4475.

Wells Fargo first reported a position in CABA in Q4 2019 and has held it in 27 quarters since. The position peaked at $941K in Q2 2020. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Wells Fargo held 196,872 shares of Cabaletta Bio worth $612K as of Q2 2026.
  • Wells Fargo bought 190,872 Cabaletta Bio shares in Q2 2026, an estimated $628K.
  • Cabaletta Bio made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4475 holding.
  • Wells Fargo first reported a position in Cabaletta Bio in Q4 2019 and has held it in 27 quarters since.
  • Wells Fargo's Cabaletta Bio position peaked at $941K in Q2 2020.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.